GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » EV-to-FCF

Sprint Bioscience AB (OSTO:SPRINT) EV-to-FCF : 3.20 (As of May. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sprint Bioscience AB's Enterprise Value is kr48.22 Mil. Sprint Bioscience AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was kr15.08 Mil. Therefore, Sprint Bioscience AB's EV-to-FCF for today is 3.20.

The historical rank and industry rank for Sprint Bioscience AB's EV-to-FCF or its related term are showing as below:

OSTO:SPRINT' s EV-to-FCF Range Over the Past 10 Years
Min: -181.95   Med: -4.59   Max: 4.13
Current: 3.1

During the past 13 years, the highest EV-to-FCF of Sprint Bioscience AB was 4.13. The lowest was -181.95. And the median was -4.59.

OSTO:SPRINT's EV-to-FCF is ranked better than
58.04% of 367 companies
in the Biotechnology industry
Industry Median: 9.77 vs OSTO:SPRINT: 3.10

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Sprint Bioscience AB's stock price is kr1.262. Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.120. Therefore, Sprint Bioscience AB's PE Ratio for today is 10.52.


Sprint Bioscience AB EV-to-FCF Historical Data

The historical data trend for Sprint Bioscience AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB EV-to-FCF Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.06 -4.53 -2.81 - 3.49

Sprint Bioscience AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.83 3.28 3.49 2.12

Competitive Comparison of Sprint Bioscience AB's EV-to-FCF

For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's EV-to-FCF falls into.



Sprint Bioscience AB EV-to-FCF Calculation

Sprint Bioscience AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=48.222/15.078
=3.20

Sprint Bioscience AB's current Enterprise Value is kr48.22 Mil.
Sprint Bioscience AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr15.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sprint Bioscience AB  (OSTO:SPRINT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sprint Bioscience AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.262/0.120
=10.52

Sprint Bioscience AB's share price for today is kr1.262.
Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sprint Bioscience AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB (OSTO:SPRINT) Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB (OSTO:SPRINT) Headlines

No Headlines